UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 19, 2005

GENTA INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

0-19635     33-0326866
(Commission File Number)     (IRS Employer Identification No.)
   
Two Connell Drive
Berkeley Heights, NJ
    07922
(Address of Principal Executive Offices)     (Zip Code)


(908) 286-9800
(Registrant’s Telephone Number, Including Area Code)


(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 


 

Item 8.01 Other Events.

On September 19, 2005, Genta Incorporated (Nasdaq: GNTA) issued a press release which announced the presentation of results from extended follow-up of patients enrolled in the Company’s Phase 3 randomized trial of Genasense® (oblimersen sodium) Injection plus chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). In addition to the previously announced significant increase in major response (the trial’s primary endpoint), the new data show significantly longer remission duration and significantly lower risk of relapse. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

     (d) Exhibits.

Exhibit
Number
          Description

 
 99.1   Press Release dated September 19, 2005

 


 

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    GENTA INCORPORATED
     

Date:  September 19, 2005 By:    /s/ William P. Keane
  
  
        Name:   
William P. Keane
      Title:  Senior Vice President, Chief Financial Officer and Corporate Secretary

 


 

EXHIBIT INDEX

Exhibit
Number
  Description Sequentially
Numbered Page
        
99.1   Press Release dated September 19, 2005